Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Boji Medical and Great Bay Bio Form JV for Long-Acting Anemia Biologic

publication date: Oct 18, 2019

Guangzhou Boji Medical Biotech, a CRO, formed a JV with Great Bay Bio of Hong Kong to develop GBB101, a novel long-acting injectable biologic designed to treat anemia caused by chronic kidney disease. Great Bay is an AI-based CMC CDMO focused on innovative biologics. The two companies, which expect GBB101 to be one of the first long-acting anti-anemia products from a China biopharma, will each invest capital in the JV, though details were not provided. More details....

Stock Symbols: (SHE: 300404)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.